Elemental Oral Iron Supplementation in Iron-Deficient Heart Failure Patients in Nigeria (ELOISE-AID-HF) STUDY

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202504672239720

Enrollment

200

Registered

2025-04-07

Start date

2025-05-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Circulatory System Cardiology

Interventions

Oral iron replacement with elemental iron in iron deficient heart failure subjects

Control group of sixty iron deficient heart failure subjects

Control Heart Failure subjects who are not iron deficient

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Having had a diagnosis of heart failure and being followed up at the clinic for heart failure in the clinic for at least six months 2. being adults >18 years old, 3. and giving their informed consent 4. Having shown to have iron deficiency by the iron panel results including serum iron, transferrin and serum ferritin.

Exclusion criteria

Exclusion criteria: 1. they refuse to give consent 2. less than 18 years 3. Had chronic kidney disease 4. have other medical conditions such as mental illness, pregnant or history of anaphylaxis to oral iron supplementation.

Design outcomes

Primary

Measure	Time frame
The primary endpoint in this study will be measured using the proportion of participants who had their iron deficiency status corrected after 16 weeks of study. Other parameters will include changes in packed cell volume, mean corpuscular hemoglobin concentration, and mean hemoglobin concentration. Other primary endpoints will be changes in the serum NT-Pro BNP measurement, electrolytes and urea changes	—

Measure

Time frame

The primary endpoint in this study will be measured using the proportion of participants who had their iron deficiency status corrected after 16 weeks of study. Other parameters will include changes in packed cell volume, mean corpuscular hemoglobin concentration, and mean hemoglobin concentration. Other primary endpoints will be changes in the serum NT-Pro BNP measurement, electrolytes and urea changes

—

Secondary

Measure	Time frame
The secondary endpoints of this study will include assessments of the impact of oral iron supplementation on the functional and clinical outcomes of HF subjects. This will include the six(6) minute walk distance, plasma NT-pro BNP levels; and Health Status using the Kansas City Cardiomyopathy Questionnaire (KCCQ) score. The relative changes in these parameters during these study will be assessed and used to evaluate the clinical and functional outcome of oral iron supplementation in HF subjects in Africa	—

Measure

Time frame

The secondary endpoints of this study will include assessments of the impact of oral iron supplementation on the functional and clinical outcomes of HF subjects. This will include the six(6) minute walk distance, plasma NT-pro BNP levels; and Health Status using the Kansas City Cardiomyopathy Questionnaire (KCCQ) score. The relative changes in these parameters during these study will be assessed and used to evaluate the clinical and functional outcome of oral iron supplementation in HF subjects in Africa

—

Countries

Nigeria

Contacts

Public ContactIfeoluwa Adeyeye

Research Assistant

emmanuel.adeyeye@yamil.com+2348162746364

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026